| Ytd | -33.59% | |
| 1y | -60.22% |
| Open | 3.06 | Prev Close | 3.01 | Low | 3.06 | High | 3.06 | Mkt Cap | 7.52M |
| Vol | 6.57K | Avg Vol | 107.04K | EPS | -5.63 | P/E | N/A | Forward P/E | -0.24 |
| Beta | 0.40 | Short Ratio | 0.77 | Inst. Own | 3.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.20 | 200-d Avg | 4.77 | 1yr Est | 1.30 |
ACON News
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driv
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release D
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”)
BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Add
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro
Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. S
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the
BROOMFIELD, Colo., May 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio
BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (N
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other
Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflect
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus E
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consens
BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio
Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise
“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Ne
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit
BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (N
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Patent covers use of AI in workflows of future products to accelerate company's ability to scale
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the
Aclarion, Inc. (NASDAQ:ACON, ACONW))) ("Aclarion" or the "Company") today announced
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasi
Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance shee
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial mo
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Acce
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a succes